Highlights Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 16/01/2026 pm IST			5-day change	1st Jan Change
2,185.00 ^DKK	+0.97%		+0.14%	+7.79%

17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI

Highlights

17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
29/12	Genmab Discontinues Development of Tumor Treatment Acasunlimab	MT
29/12	Genmab A/S Reaffirms Earnings Guidance for the Year 2025	CI
29/12	Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review	CI
12/12	Genmab Finalizes Tender Offer for Dutch Biotech Merus	MT
12/12	Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment	FW
12/12	Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V.	RE
11/12	Genmab A/S completed the acquisition of Merus N.V. in a tender offer transaction.	CI
10/12	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT
09/12	Genmab shares encouraging early-stage data on epcoritamab for RT patients	RE
09/12	Genmab A/S Announces New and Updated Data from Three arms of the Ongoing Phase 1b/2 EPCORE®? CLL-1 Trial	CI
06/12	Genmab A/S Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma and Follicular Lymphoma (FL)	CI
04/12	Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	CI
02/12	Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod	MT
02/12	Genmab's Cervical Cancer Drug Gets UK Regulatory Approval	MT
19/11	Genmab Secures US Approval for Follicular Lymphoma Combo Therapy	MT
18/11	Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
11/11	Fitch Assigns First-time Rating to Genmab with Stable Outlook	MT
10/11	Genmab Plans $2.5 Billion Notes Offering, Launches Syndication of $2 Billion Term Loan	MT
10/11	Genmab announces proposed private offerings	RE
07/11	Genmab advances on earnings strength and pipeline while lower valuation opens upside
06/11	Genmab A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Genmab advances on earnings strength and pipeline while lower valuation opens upside

November 07, 2025 at 08:31 pm IST

Genmab: From now on, courage to the most patient

April 01, 2025 at 08:27 pm IST